

M&A activity support Wednesday, February 17

Equity rotation into cyclicals, with 'bond-proxies' falling as yields surged. Risks from investor euphoria and pace, not direction, of yield rise. We focus on cyclical and intl. catch-up themes, and see markets better supported than feared. HOT TOPICS shows M&A has rebounded strongly, in-line with public markets. As growth visibility improves, financing remains cheap, and SPAC and PE 'dry powder' unprecedented we see M&A gains helping underpin equity markets.

Flat markets masked big cyclicals rotation and 'bondproxies' fall as 10-yr yields surged. Risks from signs of investor euphoria, with Bank of America Feb. fund manager survey showing investor cash at 2013 pre-taper-tantrum lows, and pace, not direction, of yield increase. Jan 22, *Impact of higher yields*. Positive virus news as J&J sent single-dose vaccine for EU Medicines Agency approval. **We focus on cyclical and intl. catch-up themes.** Asian markets were firm, with Europe and US futures flat this morning. See our latest <u>video catch-up</u> with research platform Nucleus 195, on **reflation trade and small caps**.

Key Markets Pe	rformanc	e Table		
Index	Level	1D	1W	YTD
S&P500	3934.8	-0.1%	0.5%	4.7%
ACWI xUS	56.7	0.5%	1.7%	7.5%
DXY USD	90.5	0.0%	0.1%	0.6%
US 10Y YLD	1.20	9.2%	13.3%	43.7%
Brent Spot	64.7	-0.4%	6.5%	26.6%
Gold Spot	1794.3	-1.3%	-2.3%	-5.4%

EU earnings surprise. Near halfway for Q4 earnings, and 66% 'beaten' EPS forecasts by avg. 18%, down from early highs but still above normal. Top-line growth the gap, -10% yoy and Q4 ests. missing by avg. 2.2%. Financials, IT, energy, led beats, with



HIGHLIGHTS FROM REST OF DOC

- Hot Topics on <u>M&A Support</u>. As growth visibility improves, financing remains cheap, and SPAC and PE 'dry powder' unprecedented we see M&A gains helping underpin equity markets.
- What to watch: Resilient Feb. US industrial production & retail sales. Dovish FOMC minutes..
- Country and Sector 'Eye': Favor US and EM, and cyclicals/value and IT sector barbell.
- Data pages: Performance, valuation, earnings, macro forecasts. See Library for prior dailies

*Sources if not stated are Refinitiv, THR

US & Sector Performance

Index	Level	1D	1W	YTD
S&P500	3934.8	-0.1%	0.5%	4.7%
NASDAQ	13807.7	-0.3%	0.3%	9.0%
Russell 2000	2289.4	-0.7%	-1.1%	15.1%
US IT	522.2	-0.2%	1.2%	7.7%
US Healthcare	437.8	-1.2%	-0.4%	4.5%
US Financials	215.6	1.7%	2.3%	9.9%

defensives. utilities, real estate only misses. <u>Consensus</u> for -20% yoy EPS (-15% ex energy). Germany +13% yoy leads majors, with UK lagging at -62%. Jan. 21, *Europe's earnings leverage*. Lags US performance, but Europe' macro headwinds greater, **leading to stronger 2021 rebound**.

Buffett's Berkshire bets. Latest <u>filing</u> shows cUS\$9bn new stakes in value stocks Verizon, largest US wireless carrier, and oil major Chevron, as of Dec. 31. Also trimmed healthcare, financials, and largest position Apple. Saw big gains on his surprise mid-2020 US\$6bn investment in Japanese trading houses. Berkshire stock has lagged S&P 500 8pp last 12-mths but has **cUS\$150bn cash and been accelerating share buybacks** to become one of US top 10, and trading at only 1.25x P/BV. See Jan. 29, *Biggest buyer coming back*.

Food price pressures. Kraft Heinz and Conagra said at Consumer Analyst Group of New York virtual annual conference they may raise prices as food input costs increase. US food prices have outpaced inflation, rising 3.5% yoy whilst UN food inflation index at c7-yr high, on increased demand and supply disruptions. Has driven a widening 35% 1-yr and 12% YTD divergence

FX, Fixed Income,	Commodities
-------------------	-------------

Index	Level	1D	1W	YTD
DXY USD Index	90.5	0.0%	0.1%	0.6%
EUR/USD	1.21	-0.2%	-0.1%	-0.9%
US 10Y YLD	1.20	9.2%	13.3%	43.7%
US 10-2 BOND	1.09	-1.6%	8.2%	42.1%
CBOE VIX Index	20.0	7.5%	-1%	-6%
CRB Index	3440.5	1.0%	2.5%	12.2%

Events to Watch			
Indicator	Period	Forecast	Last
Core CPI YY, UK	Jan	1.32	1.40
Retail Sales MM, US	Jan	1.34	-0.70
Industrial Production, US	Jan	0.47	1.60

between global ag. producers (Deere, ADM etc) and consumers (Nestle, Mondelez etc) index. See Sept. 18, *La Nina agricultural catalyst*.

Sector Views

Flat S&P 500 saw cyclicals energy (+2.3%) and financials (+1.8%) lead and 'bond proxies' utilities (-1.1%) and real estate (-1.1%) lag. **Shorts down not out.** Chinese drone manufacturer EHang Holdings (EH) plunged 62% after Wolfpack Research published 'shortreport' questioning co's business. See Jan. 14, *Short sellers and activists.* **Nestle selling it's US water brands** to two private equity firms for US\$4.3bn, as the PE industry continues to leverage its huge US\$1.4trn 'dry powder, supporting M&A and valuations.

What to Watch

EU new car sales plunged 24% yoy in Jan., led down by Spain and Germany, as renewed lockdown measures drove double-dip recession but setting up for sharp 2H rebound. Today see US Jan. retail and IP strength likely. US Jan. retail sales and IP both likely to underpin relative economic momentum, est. +1.3% and 0.5% respectively vs prior month, boosted by latest December fiscal stimulus plan, incl. US\$600 individual cheques. Also Fed FOMC Jan. meeting minutes. Expect a continued dovish message with the market focus on any stimulus withdrawal timing commentary, and March/April inflation 'spike' outlook.

HOT TOPICS

M&A ACTIVITY SUPPORT

M&A has rebounded strongly, in-line with public markets. Whilst unsurprisingly tech-led it has broadened by sector and geography, with a noteworthy pick-up US-China activity despite the poor bilateral rhetoric. As growth visibility improves, financing remains cheap, and SPAC and PE 'dry powder' unprecedented we see M&A gains helping underpin equity

What M&A rebound tells us

M&A has rebounded sharply from Covid lows, in-line with public markets surge. Deal activity has continued to accelerate, and healthily broaden by sector and with a larger cross-border component. Tech unsurprisingly surpassed traditional healthcare, energy, financials sectors as main focus. SPAC and PE capital levels are unprecedented. See Oct. 30th, M&A validation.

PE and SPAC's significant M&A players

Both remain significant players in M&A surge, with currently 327 SPAC's, with US\$103bn raised, looking for acquisitions. Whilst global PE 'dry powder' is near a record US\$1.4trn. See Feb. 11th, *Read-across from private equity*.

A bad year for M&A activity

US 2020 M&A activity saw the smallest deal value since 2013, with total reaching almost US\$2.1trn, a 18% decline vs 2019 and over 35%



down from the 2015 record US\$3.2tn. Deal volumes saw a bigger 22% fall to 18k transactions, the lowest in five years.

....but a sharp recovery from Q2 lows

COVID crisis unsurprisingly saw deals pulled, most notably in 1H, led by Xerox cUS\$35bn bid for HP. Activity recovered remarkably quickly from the April low though, mirroring the 100-day and +50% magnitude and speed of the S&P 500 recovery. April saw just US\$14bn and 1,400 M&A figures, but since then has strongly recovered (see chart below). The second half of 2020 saw 16% more transactions but over 3x greater deal value.

2020 M&A fall led by domestic deals

Domestic M&A deal value led the overall fall with a 40% decline in 2020. It's overall share of total M&A fell to an all-time low 54%, vs 74% prior year. By contrast, cross border



US 2020 M&A Activity



M&A value saw a 43% increase to US\$950bn, led by outbound transactions whose value more than doubled yoy.


Pick up in cross-border led by China

A notable US cross border deal pick up was seen with China and HK, which saw total inbound M&A value rise near 6x to US\$29bn, and represented over 10% of total value, after four years of declines. Outbound deal volume also rose almost 3x to 330 transactions, despite continued high-level bilateral tensions.

Tech sectors unsurprisingly led growth

Only three US sectors saw positive yoy deal value growth in 2020, unsurprisingly led by communications and IT. Communications led domestic growth, seeing over double the deal value of 2019, whereas IT saw the biggest increase in cross boarder activity, again doubling

Biggest US M&A Deals YTD



in deal value from the prior year. This supplanted the traditional leadership of healthcare, energy, and financials.

US still dominates global deals

US involved M&A deals (inbound or outbound) made up half of global deal value and over 1/3 of overall volume last year and dominated in select sectors such as IT and healthcare, making up c75% of deal value. By contrast, US Financials made up c40% share of both global sector M&A value and volume.

2021 starting stronger, with bigger deals


US M&A activity in 2021 has started strongly, with US\$350bn deal value announced so far, over double the US\$140bn seen at this prepandemic stage of 2020, and with a significantly larger average deal size. Additionally, two of the three largest announced deals have been cross-border.

Acquirer			Target	Deal Information					
Name	Nation	Sector	Name Nation		Sector	Announced	Size (US\$bn)	Transaction	Status
Investor Group	US	FIN	Suez SA	FR	UTL	17/01/2021	28	Merger	Pending
UnitedHealth Group	US	HEA	Change Healthcare	US	HEA	06/01/2021	14	Merger	Pending
American Tower	US	REA	Telxius Telecomms	ES	COM	13/01/2021	9	Acquisition	Pending
Social Capital Hedosophia	US	FIN	Social Finance	US	FIN	07/01/2021	9	Merger	Pending
Teledyne Technologies	US	IΤ	FLIR Systems	US	IND	04/01/2021	8	Merger	Pending
Corelogic	US	FIN	Corelogic	US	FIN	04/02/2021	8	Merger	Pending
Foley Trasimene Acquisition	US	FIN	Alight Solutions	US	IT	25/01/2021	7	Merger	Pending
Peraton	US	IND	Perspecta	US	IT	27/01/2021	7	Merger	Pending
FAST Acquisition	US	FIN	Fertitta Entertainment	US	CND	01/02/2021	7	Merger	Pending
Dragoneer Growth Opportunities	s US	FIN	CCC Information Services	US	IT	03/02/2021	7	Merger	Pending

COUNTRY 'EYE' & ALLOCATIONS

Country Allocation Views

Market	Main Index	THR View	Market	Main Index	THR View
US	S&P 500	Overweight	UK	FTSE 100	Underweight
EM	MSCI EM	Overweight	Canada	S&P/TSX	Overweight
Eurozone	EUROSTOXX	Neutral	Switzerland	SMI	Neutral
Japan	TOPIX	Underweight	Australia	S&P/ASX	Neutral




Source: Refinitiv, THR. SEE PAGE 13 FOR FULL METHODOLOGY

AUS=Australia, BR=Brazil, CA=Canada, CN=China, FR=France, DE=Germany, HK=Hong Kong, IN=India, ID=Indonesia, IT=Italy, JP=Japan, KR=Korea, MY=Malaysia, MX=Mexico, NL=Netherlands, NO=Norway, RU=Russia, SG=Singapore, ZA=South Africa, ES=Spain, SW=Sweden, CH=Switzerland, TW=Taiwan, TH=Thailand, UK=United Kingdom, US=United States, EU=Europe, LAT=Latin America, EM=Emerging Markets, EE=Emerging Europe, EA=Emerging Asia.

US SECTOR 'EYE' & ALLOCATION

US Sector Allocation Views

Market	Main ETFs	THR View	Market	Main ETFs	THR View
IT	XLK/VGT	Overweight	Staples	XLP/VDC	Overweight
Healthcare	XLV/VHT	Neutral	Energy	XLE/VDE	Neutral
Financials	XLF/VFH	Neutral	Utilties	XLU/VPU	Underweight
Communications	XLC/VOX	Overweight	Real Estate	XLRE/VNQ	Overweight
Discretionary	XLY/VCR	Neutral	Materials	XLB/VAW	Underweight
Industrials	XLI/VIS	Overweight			



Source: Refinitiv, THR. SEE PAGE 13 FOR FULL METHODOLOGY


AUT=Auto & Auto parts, BIS=Banking & Investment, CAP=Capital Goods, CMS=Commercial & Prof Svcs, CDU=Consumer Durables & Apparel, CSV=Consumer Svcs, DIV=Diversified Financials, ENE=Energy, FRT=Food Staples & Retail, FBV=Food, Bev. & Tobacco, HEQ=Healthcare Equipt. & Svcs, HHP=Household & Personal Products, INS=Insurance, MAT=Materials, MED=Media & Entertainment, PHA=Pharma, Bio & Life Svcs, REA=Real Estate, RET=Retailing, SEM=Semiconductors & Equipt, SFW=Software and Svcs, TCH=Technology Hardware & Equipt, TEL=Telecoms TPT=Transport, UTL=Utilities

'EYE' ALLOCATION BREAKDOWN

Country/ Region	Rationale	P/E 2020e	(x) 2021e	EPS 6 2020e	
	United States (Overweight): Remains global equity 'safer haven' despite centre COVID outbreak. Has relatively closed economy and stock market, growth and 'tech'-focused equity market, unprecedented policy response with unlimited QE and initial 15%/GDP fiscal stimulus. Valuations fundamentally supported by tech, tax, and UST. Earnings expectations well-supported. Is in 'momentum' Eye quadrant, with some of world's strongest relative fundamentals, but also some of most optimistic investors.	27.9	22.8	-9.7	22.5
*:	Emerging Markets (Overweight): We are focused on cyclical components, such as LatAm/CEEMEA, alongside more 'structural' north Asia overweight. Recent outperformance has a lot further to go after decade of under-performance, with GDP, earnings, valuations, currencies, and ownership all depressed, with room for a sharp 2021 recovery as gain vaccine-led growth visibility. Frontier and EM proxies (such as Canada/Spain) also attractive. Key is accelerating earnings turn-around, which is currently weak.	21.9	16.2	-6.0	35.2
**** * * * *	Eurozone (Neutral): Led global GDP and EPS decline, whilst much of valuation discount vs US is just sector composition. Recession triggered a broader fiscal policy response, whilst ECB help extended. COVID easing and countries reopening will see large cyclical economic and market upturn. Focus on cheap domestic cyclicals, such as Financials. Risk is impact of stronger EUR on region's globalised and low margin companies.	23.7	17.2	-30.1	37.7
	Japan (Underweight): Been moving out of the value-trap 'Eye' quadrant, but has significant fundamental headwinds on growth, trade, policy flexibility, and longer-term structural issues (demographics, debt). Valuation is attractive vs history, but EPS outlook overstated and vulnerable to stronger JPY. Domestic stocks underperformed global-exposed peers.	23.9	17.5	-3.7	36.8
	UK (Underweight): In value-trap framework quadrant. Exposed to twin-headwinds of above- average COVID impact (with high infections and relatively low fiscal response) and Brexit impacts (after 'lite' goods-focused Brexit deal), and market valuations at long-term average. Risk that lags our preferred recovery cyclicals (Canada, EU Financials, US small caps) despite 50%+ cyclical equity index composition and 60% overseas revenue exposure.	20.9	14.1	-38.2	48.0
US Sector	Rationale	P/E 2020e		EPS 6 2020e	Gr. (%) 2021e
US Sector	Rationale Information Technology (Overweight): See resilient to cyclicals catch up (not rotation) given still strong long-term growth and financial flexibility and still relatively well positioned on allocation framework. Software in attractive 'momentum' quadrant. Valuations average but supported by net-cash and high RoE, giving buyback and M&A flexibility. Tech Hardware				
US Sector	Rationale Information Technology (Overweight): See resilient to cyclicals catch up (not rotation) given still strong long-term growth and financial flexibility and still relatively well positioned on allocation framework. Software in attractive 'momentum' quadrant. Valuations average but supported by net-cash and high RoE, giving buyback and M&A flexibility. Tech Hardware (Neutral) less well positioned, but beneficiary of easing growth concerns. Healthcare (Neutral): Both Healthcare Equipment and Pharma have been slipping on our framework, and sector remain liked by the market (with multiple rerating and sell-side conviction). We see quality growth vulnerable at this stage, with market less rewarding of defensive cash flows, less EPS cyclicality and domestic revenue focus. Seeing Federal support to combat COVID. Similar to Tech, seeing accelerated adoption drivers.	2020e	2021e	2020e	2021e
US Sector	Rationale Information Technology (Overweight): See resilient to cyclicals catch up (not rotation) given still strong long-term growth and financial flexibility and still relatively well positioned on allocation framework. Software in attractive 'momentum' quadrant. Valuations average but supported by net-cash and high RoE, giving buyback and M&A flexibility. Tech Hardware (Neutral) less well positioned, but beneficiary of easing growth concerns. Healthcare (Neutral): Both Healthcare Equipment and Pharma have been slipping on our framework, and sector remain liked by the market (with multiple rerating and sell-side conviction). We see quality growth vulnerable at this stage, with market less rewarding of defensive cash flows, less EPS cyclicality and domestic revenue focus. Seeing Federal support to combat COVID. Similar to Tech, seeing accelerated adoption drivers. Financials (Neutral:All segments been improving on allocation framework, and remain out of favour with market, with strong fund outflows and valuation derating. Fundamental outlook improving with higher bond yields, GDP recovery, and less regulatory capital restrictions. However, likely 'caps' on how high bond yields can go and less EPS operating leverage than cyclicals are constraints Insurance offers the best value in our view, though none of the	2020e 34.7	2021e 29.1 17.0	<u>2020e</u> 6.2	2021e 19.5 14.5
	Rationale Information Technology (Overweight): See resilient to cyclicals catch up (not rotation) given still strong long-term growth and financial flexibility and still relatively well positioned on allocation framework. Software in attractive 'momentum' quadrant. Valuations average but supported by net-cash and high RoE, giving buyback and M&A flexibility. Tech Hardware (Neutral) less well positioned, but beneficiary of easing growth concerns. Healthcare (Neutral): Both Healthcare Equipment and Pharma have been slipping on our framework, and sector remain liked by the market (with multiple rerating and sell-side conviction). We see quality growth vulnerable at this stage, with market less rewarding of defensive cash flows, less EPS cyclicality and domestic revenue focus. Seeing Federal support to combat COVID. Similar to Tech, seeing accelerated adoption drivers. Financials (Neutral:All segments been improving on allocation framework, and remain out of favour with market, with strong fund outflows and valuation derating. Fundamental outlook improving with higher bond yields, GDP recovery, and less regulatory capital restrictions. However, likely 'caps' on how high bond yields can go and less EPS operating leverage than	2020e 34.7 19.5	2021e 29.1 17.0	2020e 6.2 9.2	2021e 19.5 14.5

Source: Refinitiv, THR


Total Return YTD



		Price Performance				PE			EPS Growth	
Index	Abbreviation	1D (%)	1W (%)	3M(%)	YTD (%)	2019A	2020E	2021E	2020E	2021E
World	AC	0.0	1.2	11.6	6.0	21.9	25.6	19.8	-14.6%	28.9%
EAFE	EAFE	0.1	2.1	11.3	5.1	18.0	24.0	17.5	-24.7%	37.0%
Europe	EU	-0.2	2.3	9.9	4.1	16.6	23.7	17.2	-30.1%	37.7%
Asia	AS	0.5	2.1	17.6	10.4	22.5	22.8	17.6	-1.2%	30.0%
Emerging Global Markets	EM	0.3	2.3	19.9	11.7	20.6	21.9	16.2	-6.0%	35.2%
Emerging Asia	EA	0.5	2.5	21.4	13.6	23.3	22.1	17.7	5.3%	25.3%
Australia	AUS	0.7	1.4	7.3	5.3	23.9	21.3	18.8	12.4%	13.0%
Brazil	BR	0.0	0.0	12.1	0.4	16.2	36.8	11.4	-56.0%	222.9%
Canada	CA	0.2	0.8	9.4	5.8	15.8	20.8	16.1	-24.1%	28.7%
China	CN	0.8	3.1	20.6	18.8	21.0	20.6	17.4	1.8%	18.4%
France	FR	0.0	1.5	5.3	4.2	16.3	29.4	17.9	-44.7%	64.0%
Germany	DE	-0.1	0.9	8.9	3.5	17.7	22.9	16.3	-22.8%	40.5%
Hong Kong	HK	2.2	4.0	14.7	10.2	17.3	23.5	17.9	-26.4%	31.6%
India	IN	-0.1	1.7	18.0	8.1	30.4	30.2	22.3	0.6%	35.9%
Indonesia	ID	0.2	0.6	6.8	1.6	17.3	23.0	17.4	-24.9%	32.1%
Italy	п	-0.7	0.5	9.2	4.2	11.5	21.0	13.6	-45.4%	55.1%
Japan	JP	0.7	2.5	14.8	9.5	23.0	23.9	17.5	-3.7%	36.8%
Korea	KR	0.4	2.6	26.5	9.4	27.8	22.2	15.1	25.6%	46.3%
Malaysia	MY	0.0	1.2	-1.0	-1.5	18.0	22.5	13.5	-19.9%	66.4%
Mexico	MX	1.3	-0.7	9.0	1.3	18.0	25.8	15.0	-30.3%	72.5%
Netherlands	NL	0.3	5.0	18.7	13.9	27.1	29.8	24.9	-9.2%	19.9%
Norway	NO	0.1	-0.2	4.0	1.4	15.9	21.6	15.8	-26.1%	36.8%
Russia	RU	0.2	2.1	13.3	5.7	6.9	12.9	8.1	-46.4%	59.0%
Singapore	SG	0.2	0.3	7.1	3.3	13.2	21.3	14.6	-38.2%	46.6%
South Africa	ZA	-0.8	2.5	14.5	13.0	17.5	17.2	11.2	1.8%	52.8%
Spain	ES	-0.7	0.7	2.9	1.1	12.0	21.4	15.6	-44.1%	37.0%
Sweden	SE	0.0	1.9	8.2	8.8	19.0	24.2	19.3	-21.2%	25.3%
Switzerland	СН	-0.2	1.0	2.7	1.6	20.9	22.5	19.5	-7.1%	15.1%
Taiwan	TW	0.0	0.0	21.9	11.8	27.2	22.2	19.4	22.7%	14.6%
Thailand	ТН	0.2	0.0	9.4	4.0	16.5	26.7	20.1	-38.2%	32.7%
United Kingdom	UK	-0.1	3.4	4.7	4.4	12.9	20.9	14.1	-38.2%	48.0%
United States	US	-0.1	0.6	9.9	5.1	25.2	27.9	22.8	-9.7%	22.5%


Source: MSCI, Refinitiv, THR

Total Return YTD



		Price Performance				PE			EPS Growth	
Index	Abbreviation	1D (%)	1W (%)	3M(%)	YTD (%)	2019A	2020E	2021E	2020E	2021E
United States	US	-0.1	0.6	9.9	5.1	25.2	27.9	22.8	-9.7%	22.5%
Communications	COM	0.4	1.1	11.4	7.5	26.9	27.6	24.4	-2.4%	12.9%
Media & Entertainment	MED	0.5	1.4	14.7	9.7	35.6	36.1	30.4	-1.5%	18.9%
Telecommunication Svcs	TEL	0.0	-0.6	-4.9	-3.8	11.2	11.7	11.4	-4.1%	2.0%
Consumer Discretionary	CND	-0.5	-1.4	10.1	5.7	43.1	56.7	37.3	-24.0%	51.9%
Autos & Components	AUT	0.2	1.6	25.1	13.9	56.1	88.6	44.6	-36.7%	98.4%
Consumer Durables & App	CDU	-1.2	-0.9	13.9	7.4	31.4	26.9	21.0	16.5%	28.4%
Consumer Svcs	CSV	0.3	0.3	9.3	3.3	24.3	NA	60.3	-114.6%	NA
Retailing	RET	-0.2	-0.8	6.8	3.4	49.7	46.7	37.0	6.5%	26.1%
Consumer Staples	CNS	-0.2	-0.6	-2.7	-2.5	22.4	21.5	20.3	4.0%	6.1%
Food & Staples Retailing	FRT	0.2	-0.6	-1.6	1.0	25.2	24.6	24.3	2.3%	1.3%
Food, Bev & Tobacco	FBV	-0.5	-0.8	-1.0	-2.5	19.2	18.8	17.7	2.3%	6.4%
Household Products	HHP	-0.2	-0.8	-9.4	-7.3	27.7	24.6	22.6	12.6%	9.0%
Energy	ENE	2.3	4.1	28.1	20.6	14.8	NA	25.8	-108.6%	NA
Financials	FIN	1.7	2.3	16.1	8.9	13.2	16.2	13.2	-18.5%	23.3%
Banks	BIS	2.6	3.4	25.0	14.0	10.3	15.2	11.8	-32.3%	28.9%
Diversified Financials	DIV	1.4	2.1	13.2	6.9	17.5	18.6	15.6	-5.7%	19.2%
Insurance	INS	0.1	0.0	5.2	2.8	12.8	14.0	11.5	-8.5%	21.2%
Health Care	HEA	-1.0	0.0	5.0	2.9	21.3	19.5	17.0	9.2%	14.5%
Health Care Equipment	HEQ	-0.7	1.5	7.6	5.3	35.7	36.2	27.5	-1.4%	31.4%
Pharmaceuticals	PHA	-0.7	0.0	5.8	1.5	16.8	15.8	14.1	6.4%	12.1%
Industrials	IND	-0.1	0.3	4.9	3.0	23.2	30.2	23.1	-23.3%	31.0%
Capital Goods	CAP	-0.2	0.1	6.0	3.5	20.1	28.8	22.2	-30.2%	29.6%
Commercial & Prof Svcs	CMS	-0.4	-0.9	0.7	-0.5	35.1	34.3	31.0	2.5%	10.6%
Transportation	TPT	0.2	1.6	3.4	3.2	32.4	33.1	22.7	-1.9%	45.7%
Information Technology	TEC	-0.3	1.1	13.8	6.3	36.9	34.7	29.1	6.2%	19.5%
Semiconductors	SEM	0.6	4.6	19.0	12.2	27.1	25.5	21.8	6.3%	17.0%
Software & Svcs	SFW	-0.1	0.9	10.9	5.3	43.8	40.7	34.5	7.5%	17.9%
Technology Hardware	тсн	-1.3	-1.4	13.1	2.8	35.3	33.8	27.3	4.4%	23.6%
Materials	МАТ	-0.1	0.9	7.3	3.3	23.7	25.8	19.9	-8.2%	29.3%
Real Estate	REA	-0.9	-0.2	2.9	4.2	35.7	50.7	49.3	-29.7%	2.9%
Utilities	UTE	-1.0	-2.0	-6.7	-1.4	17.7	18.5	18.0	-4.4%	2.8%

Source: MSCI, Refinitiv, THR




CRB Major Commodity Index* - 3 Years



Name	Currency	Close Price	1 Day	1 Week	1 Month	3 Months	1 Year	MTD	QTD	YTD
Commodoties	-									
CRB Commodity Index	USD	3475.23	1.0%	2.5%	3.8%	20.8%	20.3%	10.1%	12.2%	12.2%
Gold Spot	USD	1794.31	-1.3%	-2.3%	-1.8%	-5.0%	13.3%	-2.8%	-5.4%	-5.4%
Copper Spot	USD	3.85	1.2%	3.1%	6.8%	19.5%	47.7%	7.7%	9.5%	9.5%
Brent Crude Spot	USD	64.39	-0.4%	6.5%	18.1%	50.4%	11.1%	16.2%	26.6%	26.6%
CRB Agricultural Index	USD	7051.38	0.7%	1.7%	5.1%	21.1%	30.3%	9.7%	13.3%	13.3%
Currencies	-									
DXY USD Index	USD	90.51	0.0%	0.1%	-0.3%	-2.3%	-8.7%	-0.1%	0.6%	0.6%
EUR/USD	USD	1.21	-0.2%	-0.1%	0.2%	2.1%	11.8%	-0.3%	-0.9%	-0.9%
USD/JPY	JPY	106.04	0.6%	1.4%	2.1%	1.4%	-3.4%	1.3%	2.7%	2.7%
GBP/USD	USD	1.39	0.0%	0.6%	2.3%	5.4%	6.6%	1.5%	1.7%	1.7%
USD/CNY	CNY	6.45	0.0%	0.3%	-0.4%	-2.0%	-7.6%	0.5%	-1.1%	-1.1%
Bond Yields	-									
DE 10Y BUND	EUR	-0.35	-9.1%	-22.1%	-35.6%	-36.0%	-13.0%	-32.9%	-39.3%	-39.3%
GB 10Y GILT	GBP	0.62	8.6%	33.8%	115.6%	76.9%	-1.3%	89.9%	216.8%	216.8%
JP 10Y JGB	JPY	0.10	5.3%	14.3%	158.1%	281.0%	-375.9%	56.9%	281.0%	281.0%
US 10Y BILL	USD	1.30	8.3%	12.3%	18.4%	43.4%	-18.2%	18.7%	42.4%	42.4%
US 30Y BOND	USD	2.09	4.3%	7.3%	12.9%	26.0%	2.3%	12.5%	27.3%	27.3%
US 10-2 BOND	-	1.18	-2.6%	7.1%	28.6%	74.7%	73.2%	13.6%	40.8%	40.8%
Volatility	-									
CBOE VIX Index	USD	21.46	0.07	-0.01	-0.12	-0.04	0.57	-0.35	-0.06	-0.06



MACRO INDICATORS: HISTORIC AND FORECASTS



Forecast Real GDP Growth 'Delta' (2021E % Growth – 2020E)

			R	eal GDP (%)	1	nflation (%	6)	Fiscal Balance (% GDP)			Gov Debt (% GDP)	
	Carlas	Nominal GDP 2019 US\$trn	2019	2020E	2021E	2019	2020E	2021E	2019	2020E	2021E	2019	2020E
Americas		•											
US	US	21.4	2.2	-3.4	5.1	1.8	1.5	2.8	-6.3	-18.7	-8.7	109	131
Canada	CA	1.7	1.7	-5.5	3.6	1.9	0.6	1.3	-0.3	-19.9	-8.7	89	115
Brazil	BR	1.9	1.1	-4.5	3.6	3.7	2.7	2.9	-6.0	-16.8	-6.5	90	101
Mexico	MX	1.3	-0.3	-8.5	4.3	3.6	3.4	3.3	-2.3	-5.8	-3.4	54	66
Europe													
Eurozone	EU	18.3	1.7	-7.2	4.2	1.4	0.8	1.2	-0.6	-9.7	-4.8	79	95
Germany	DE	3.9	0.6	-5.4	3.5	1.3	0.5	1.1	1.5	-8.2	-3.2	60	73
UK	GB	2.7	1.5	-10.0	4.5	1.8	0.8	1.2	-2.2	-16.5	-9.2	85	108
France	FR	2.7	1.5	-9.0	5.5	1.3	0.5	0.6	-3.0	-10.8	-6.5	98	119
Italy	IT	2.0	0.3	-9.2	3.0	0.6	0.1	0.6	-1.6	-13.0	-6.2	135	162
Spain	ES	1.4	2.0	-11.1	5.9	0.7	-0.2	0.8	-2.8	-14.1	-7.5	96	123
Netherlands	NL	0.9	1.7	-4.1	3.0	2.7	1.2	1.5	1.7	-8.8	-4.9	48	59
Switzerland	СН	0.7	1.2	-5.3	3.6	0.4	-0.8	0.0	1.5	-4.2	-1.4	42	49
Sweden	SE	0.5	1.3	-4.7	3.5	1.6	0.8	1.4	0.4	-5.9	-2.0	35	42
Russia	RU	1.6	1.3	-3.6	3.0	4.5	3.2	3.2	1.9	-5.3	-2.6	14	19
Turkey	TR	0.7	0.9	1.2	6.0	15.2	11.9	11.9	-5.6	-7.9	-7.9	33	42
Asia													
China	CN	14.1	6.1	2.3	8.1	2.9	2.9	2.7	-6.3	-11.9	-11.8	53	62
Hong Kong	HK	0.4	-1.2	-7.5	3.7	2.9	0.3	2.4	-1.5	-11.8	-6.6	0	0
Japan	JP	5.2	0.7	-5.1	3.1	0.5	-0.1	0.3	-3.3	-14.2	-6.4	238	266
India	IN	2.9	4.2	-8.0	11.5	4.8	4.9	3.7	-8.2	-13.1	-10.9	72	89
Korea	KR	1.6	2.0	-1.1	3.1	0.4	0.5	0.9	0.4	-3.2	-2.3	42	48
Australia	AU	1.4	1.8	-2.9	3.5	1.6	0.7	1.3	-3.9	-10.1	-10.5	46	60
Indonesia	ID	1.1	5.0	-1.9	4.8	2.8	2.1	1.6	-2.2	-6.3	-5.5	31	39
Taiwan	TW	0.6	2.7	0.0	3.2	0.5	-0.1	1.0	-1.8	-4.7	-3.2	33	36
Thailand	TH	0.5	2.4	-6.6	2.7	0.7	-0.4	1.8	-0.8	-5.2	-4.9	41	50
Singapore	SG	0.4	0.7	-6.0	5.0	0.6	-0.4	0.3	3.8	-10.8	1.2	130	131
Other													
South Africa	ZA	0.4	0.2	-7.5	2.8	4.1	3.3	3.9	-6.3	-14.0	-11.1	62	79
World													
Developed Markets	DM	51.7	1.7	-4.9	4.3	1.4	0.8	1.6	-3.3	-14.2	-6.8	104	124
Emerging Markets	EM	34.9	3.7	-2.4	6.3	5.1	5.0	4.7	-4.8	-10.4	-8.8	52	61
World	AC	86.6	2.8	-3.5	5.5	3.5	3.2	3.4					

Source: IMF, THR



GLOBAL MACRO & FORECAST TABLES

Provides historic data, and consensus forecasts, for key macro-economic indicators in the major economies of US, Germany, and China. Forecasts highlighted in green and red indicate whether the latest change in the consensus forecast was an increase or decrease.

	Historic											Forecasts	
United States	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020E	2021E	
Production													
Real GDP, Growth	2.6	1.6	2.2	1.8	2.5	2.9	1.6	2.4	2.9	2.3	-5.7	4.0	
Industrial Production, Growth	5.5	3.1	3.0	2.0	3.1	-1.0	-1.9	2.3	3.9	0.8	-9.1	2.6	
Labour Markets and Income													
Unemployment Rate	9.6	8.9	8.1	7.4	6.2	5.3	4.9	4.3	3.9	3.7	10.5	8.0	
Average Earnings, Growth	1.9	2.0	1.9	2.1	2.1	2.2	2.6	2.6	3.0	3.3	2.8	2.4	
Prices													
CPI	1.6	3.2	2.1	1.5	1.6	0.1	1.3	2.1	2.4	1.8	1.6	1.6	
PCE, excluding energy	1.4	1.6	1.9	1.5	1.6	1.2	1.6	1.6	1.9	1.6	1.3	1.4	
Government													
Budget Balance, Growth	-0.2	-0.2	0.0	-0.9	-0.2	0.0	0.2	0.1	0.2	0.1	0.6	-0.4	
Current Account, % of GDP	-2.9	-2.9	-2.6	-2.1	-2.1	-2.2	-2.3	-2.3	-2.4	-2.5	-2.2	-2.4	

	Historic											Forecasts	
Germany	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020E	2021E	
Production													
Real GDP, Growth	4.2	3.9	0.4	0.4	2.2	1.7	2.2	2.5	1.5	0.6	-5.3	4.4	
Industrial Production, Growth	11.6	8.8	-0.6	0.3	1.9	0.4	1.4	3.6	1.2	-4.5	-7.0	5.9	
Labour Markets and Income													
Unemployment Rate	7.6	7.1	6.8	6.9	6.7	6.4	6.1	5.7	5.2	5.0	5.4	5.2	
Prices													
CPI	1.1	2.1	2.0	1.5	1.0	0.2	0.4	1.7	2.0	1.4	0.8	1.4	
Government													
Current Account, % of GDP	5.7	6.2	7.1	6.6	7.2	8.6	8.5	8.1	7.3	7.0	6.5	6.4	

		Forecasts										
China	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020E	2021E
Production												
Real GDP, Growth	9.9	8.8	8.1	7.7	7.3	6.9	6.9	6.8	6.5	6.0	1.8	8.2
Prices												
CPI	3.5	5.5	2.6	2.7	2.0	1.4	2.0	1.5	2.1	2.8	3.3	2.3
Government												
Current Account, % of GDP	3.9	1.8	2.5	1.5	2.2	2.7	1.8	1.6	0.4	1.0	0.5	0.8



TOWER HUDSON 'EYE': HOW IT WORKS

The 'eye' methodology helps identify relative buy and sell signals for countries, regions and US sectors, by comparing market sentiment vs fundamentals, with a valuation overlay. The more out-of-favor, with better relative fundamentals the better.

We compare: 1) **sentiment:** to understand whether markets are optimistic or pessimistic, and 2) **fundamentals:** focusing on earnings and business cycle fundamentals and price momentum. The output is also color-coded with a valuation overlay. This combines to give a relative allocation view

How to read the quadrants

Top left – Pessimistic sentiment/Positive fundamentals: The best place to be. Market expectations are low, but fundamentals are relatively good. As sentiment catches up to the better fundamentals, assets may outperform.

Top right – Optimistic sentiment/Positive fundamentals: The 2^{nd} best place to be. The fundamentals are good, but so is market sentiment. This is a momentum quadrant that may deliver outperformance, but investors must be sensitive to relative fundamentals easing.

Bottom right – Optimistic sentiment/Negative fundamentals: Worst place to be. Fundamentals are poor but sentiment still positive. As sentiment catches up, assets may underperform.

Bottom left – Negative sentiment/Negative fundamentals: The second worst place to be. Can be a 'value trap'. Fundamentals are weak but sentiment is equally subdued. Investors need to be sensitive to any improvement in relative fundamentals, that can lead to a move up and rerating.

Sentiment	Indicator							
Buy-side	Net ETF and Mutual Fund Flows vs average							
Sell-side	Sell-side recommendation consensus score (RCS)							
Re-rating/De-rating	Trailling P/E ratio vs average							
Fundamentals								
Earnings revisions	Rolling earnings revisions ratio							
Price momentum	Change in trailing P/E ratio							
Business cycle	Correlation to this business cycle stage (rising, neutral, falling)							
Overlay								
Valuation	Average of P/E, P/BV, and P/CF vs history							
17/02/2021	Ben Laidler ben@towerhudson.com							



LIBRARY

RECENT 'EYE ON THE WORLD' DAILIES

These reports available to **DAILY subscribers-only** through our website Library

Please let us know if you need help accessing

FEBRUARY 16: MARKETS GETTING CHEAPER

FEBRUARY 15: TAKING THE GROWTH PULSE

FEBRUARY 12: SMALL CAP FOCUS

FEBRUARY 11: READ ACROSS FROM PRIVATE EQUITY

FEBRUARY 10: UPSIDE US SURPRISE

FEBRUARY 9TH: WHAT ETFS TELL US

FEBRUARY 8TH: GROWTH OUTLOOK REFOCUS

FEBRUARY 05: THE VACCINE DIVIDE

FEBRUARY 04: RETURN OF FAANGM'S

FEBRUARY 03: REMEMBERING CORRECTIONS

FEBRUARY 02: GLOBAL EARNINGS SUPPORT

FEBRUARY 01: REFOCUS ON THE VIRUS

JANUARY 29: BIGGEST BUYER COMING BACK

JANUARY 28: RISE OF RETAIL INVESTOR

JANUARY 27: THE REAL COST OF CARBON

Subscriptions can be made, and example Daily issues seen, at www.towerhudson.com



ABOUT US

'EYE ON THE WORLD' DAILY

One idea or insight a year, or a client relationship gained or maintained, or an hour of your time saved daily. These can individually be worth many times the subscription price

US and Global investment trends and actionable views in your inbox at 7 am ET daily Each day we include:

- Multi-asset market recap
- What to watch for outlook
- Hot topic analysis and view
- 31 Countries & Regions allocation model
- 24 US sector industries allocation model
- Our key country and sector investment views
- Data on market performance, earnings, valuation, and macro-economics

Subscription also includes:

- Weekly conference call and Q&A, as well as audio replay
- Quarterly market recap and performance data, for client reporting
- **Open line** email and Q&A for us to answer your key questions
- Access to back catalogue of hot topic reports and weekly call audio

Subscriptions can be made, and example Daily issues seen, at <u>www.towerhudson.com</u>

TOWER HUDSON RESEARCH

Tower Hudson Research Ltd is an UK FCA registered firm providing investment strategy research globally. Our multi-disciplinary team of financial and investment strategy analysts provides an in-depth and global perspective and capability.

Visit us at <u>www.towerhudson.com</u> or contact us at directly <u>ben@towerhudson.com</u> or on (US) +1 917 539 0541 or (UK +44 (0) 7444 392506, with any questions.

Important Disclosure Statement from Tower Hudson Research Ltd

This document is issued by Tower Hudson Research Ltd solely for its clients. It **may not be reproduced**, **redistributed or passed to any other person** in whole or in part without written consent of Tower Hudson Research Ltd. This material is not directed at you if Tower Hudson is prohibited or restricted by any legislation in any jurisdiction from making it available to you.

This document **is provided for information purposes only** and should not be regarded as an offer, solicitation, invitation, inducement or recommendation relating to any security or other financial instrument. This document does not constitute, and should not be interpreted as, investment advice. You should seek independent advice from a suitably qualified professional advisor before taking any decisions in relation to the investments detailed herein. All expressions of opinions and estimates constitute a judgement and are those of the author and Tower Hudson Research Ltd only and are subject to change without notice. Tower Hudson is under no obligation to update information contained. Whilst we have taken all reasonable care to ensure information is not untrue or misleading at the time of publication, we cannot guarantee its accuracy or completeness.

This document **is not guaranteed to be a complete statement** or summary of any securities, markets, or developments referred to herein. No representation or warranty is made, nor responsibility of any kind is accepted, by Tower Hudson Research Ltd either as to the accuracy or completeness of any information contained in this document. No liability whatsoever is accepted by Tower Hudson Research Ltd for any loss, whether direct or consequential, arising whether directly or indirectly as a result of the recipient acting on the content of this document, including, without limitation, lost profits arising from the use of this document or any of its contents.

This document is provided with the understanding that Tower Hudson Research Ltd is **not acting in a fiduciary capacity** and it is not a personal recommendation to you. Investing in securities entails risks. The value of and the income produced by products may fluctuate, so that an investor may get back less than he invested. Investments referred to are not suitable for all investors and this document should not be relied upon in substitution for the exercise of independent judgment. The stated price of any securities mentioned herein will generally be the closing price at the end of any of the three business days immediately prior to the publication date on this document.

Tower Hudson Research Ltd and respective analysts are remunerated for providing investment research to professional investors, corporations, other research institutions and consultancy houses. **Our analysts are not censored in any way** and are free to express their personal opinions. We may have issued other documents inconsistent with conclusions from the information contained here. Those reflect different assumptions, views and analytical methods of authors at the time.

Tower Hudson Research Ltd is an **appointed representative of Messels Ltd., authorised and regulated by the Financial Conduct Authority** for the provision of investment advice. Residents of the UK should seek specific professional financial and investment advice from a professional adviser authorised pursuant to the Financial Services and Markets Act 2000. This report is intended only for investors who are 'professional clients' as defined by the FCA, and may not, therefore, be redistributed to other classes of investors.

Analysts' Certification

The analysts involved in the production of this document certify that the views expressed accurately reflect their personal views about the securities mentioned. The analysts may buy, sell or already have taken positions in the securities, and related financial instruments, mentioned.